Phil Vick­ers talks new role as head of Long­wood’s Solu af­ter Faze shut­down; Re­gen­eron CFO to re­tire in Feb­ru­ary

Phil Vick­ers start­ed last week as pres­i­dent and CEO of Solu Ther­a­peu­tics, a Long­wood Fund start­up de­vel­op­ing small mol­e­cule-an­ti­body chimeras.

He takes the place of Long­wood ex­ec­u­tive part­ner David Don­abe­di­an, who has tak­en the ear­ly CEO roles at a num­ber of com­pa­nies Long­wood has backed, in­clud­ing Ax­i­al Ther­a­peu­tics, Im­muneID and DEM Bio­Phar­ma.

Vick­ers was pre­vi­ous­ly head of Faze Med­i­cines, a con­den­sates biotech start­ed by Third Rock that launched with $81 mil­lion in 2020 be­fore shut­ting down at the end of last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER